MULTIPLE MYELOMA

This study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction, in people with relapsed or refractory multiple myeloma. About 230 participants will receive either to…

This early-phase study tests a new approach for people with high-risk multiple myeloma, including those whose cancer has returned or not responded to treatment. Participants receive a radioactive antibody that targets and kills myeloma cells, followed by chemotherapy, radiation, …

This study compares a four-drug combination (Isa-VRD) against the standard three-drug regimen (VRD) for people newly diagnosed with high-risk multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if adding isatuximab helps achieve deeper cancer remi…

This study tests whether a new drug combination (elranatamab plus standard medications) works better than the current standard (daratumumab plus standard medications) for people newly diagnosed with multiple myeloma who are not eligible for or choose not to have a stem cell trans…

This study looks at how well the drug combination melflufen (Pepaxti) and dexamethasone works for people with multiple myeloma that has come back or stopped responding to other treatments. About 50 participants will be observed in real-world clinics to measure how often the disea…

This study tests whether adding a drug called NT-I7 (IL-7) after standard CAR-T therapy can help the immune cells stay active longer and control multiple myeloma better. About 52 adults whose myeloma has returned or not responded to treatment will receive either NT-I7 or a placeb…

This study tests a drug called linvoseltamab in 34 adults with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. The goal is to see if this bispecific antibody can shrink tumors again. Participants must be at least 18 and have had CAR T therapy at least 6 mont…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults who have already tried 1-3 prior therapies will participate. The goal is to see if…

This early-phase study tests a new drug called SHR-3836 in about 99 adults with multiple myeloma that has come back or not responded to treatment. The main goals are to check safety and find the best dose. Researchers will also look at how the drug works in the body and whether i…

This study tests if a drug called emapalumab can prevent severe side effects (cytokine release syndrome and nerve toxicity) caused by bispecific antibody therapy for lymphoma and multiple myeloma. About 60 adults will receive emapalumab before starting their cancer treatment. The…

This study tests a new drug, JNJ-79635322, against another drug, teclistamab, in people whose multiple myeloma has returned or stopped responding after 1 to 3 prior treatments. About 700 adults will be randomly assigned to one of the two drugs. The goal is to see which one works …

This study tests a new drug called IBI3003 in people with multiple myeloma that has returned or stopped responding to other treatments. The goal is to find the safest and most effective dose and see how well it controls the cancer. About 360 adults will take part in this early-ph…

This trial tests whether two drugs already approved for certain skin and lung cancers can help people with rare cancers that have a specific gene change called BRAF V600. About 30 adults and children with various rare cancers will receive dabrafenib and trametinib. The goal is to…

This study tests a drug called CM336 (a BCMA/CD3 bispecific antibody) as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. The goal is to see if it can turn patients from MRD-positive (having minimal residual disease) to MRD-negativ…

This early-phase study tests a new kind of CAR T cell therapy for people with multiple myeloma that has returned or not responded to at least three prior treatments. The cells are 'armored' to resist signals from the cancer that normally shut them down. The main goal is to check …

This study tests a new drug called TQB2934 in 260 people whose multiple myeloma has returned or stopped responding to treatment. Participants will be randomly assigned to receive either TQB2934 or one of several standard treatments chosen by their doctor. The main goal is to see …

This study tests whether giving the drug daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can control multiple myeloma as well as the standard every-4-week schedule after a stem cell transplant. The goal is to reduce treatment costs and clinic v…

This early-stage study tests a new drug called BL-M24D1 in about 33 people whose multiple myeloma or other blood cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors.…

This study looks at whether using special dosing guidelines for people with the Duffy null blood trait can help them avoid treatment delays and dangerous fevers during chemotherapy for multiple myeloma or triple-negative breast cancer. About 90 participants will be enrolled, and …

This study tests a new cell therapy (BCMA-GPRC5D CAR-T) in 28 adults with relapsed/refractory multiple myeloma who have already tried three or more treatments. The goal is to see if this therapy can control the disease and improve survival. Participants receive a one-time infusio…

This study tests whether a new drug combination (belantamab mafodotin plus standard drugs) works better than the current standard (daratumumab plus standard drugs) for people newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. About 500 …

This study tests whether adding thiotepa to the standard melphalan treatment before a stem cell transplant can reduce the chance of cancer returning in people with multiple myeloma who still have signs of disease. About 204 adults aged 18-70 will be randomly assigned to receive e…

This study is for people newly diagnosed with multiple myeloma that has a specific genetic marker (+1q), which can make the disease harder to treat. Researchers will use a special scoring system to assign each person a treatment plan matched to their risk level. The goal is to se…

This study tests a new type of PET/CT scan that uses a special tracer to find BCMA, a protein on myeloma cells. The goal is to see if this scan can accurately detect active myeloma lesions compared to biopsy. About 300 people with suspected or known multiple myeloma will take par…

This study tests whether taking fish oil by mouth can prevent or reduce peripheral neuropathy—nerve damage causing pain, numbness, or tingling—in people with multiple myeloma receiving the chemotherapy drug bortezomib. About 200 adults starting bortezomib for the first time will …

This study looks at whether adding a controlled breathing routine to a standard exercise program can reduce physical symptoms like pain or fatigue in adults with multiple myeloma. About 32 people will take part in a 6-week program, with some doing extra breathing exercises at hom…

This study is testing different doses of treatments for blood cancers like multiple myeloma and Waldenstrom macroglobulinaemia. The goal is to find the dose that works best while causing fewer side effects. About 400 adults will take part, and the study will compare survival and …

This early-stage study tests whether a new drug called QL2109 works like the approved cancer drug Darzalex in healthy Chinese men. The goal is to compare how the body processes each drug and check for side effects. No treatment for multiple myeloma is given — this is a safety and…

This study tests if a small, wearable patch called TempTraq can catch fevers early in cancer patients getting immunotherapy. Fevers can be a sign of cytokine release syndrome (CRS), a serious side effect. The patch monitors temperature continuously, which may help doctors act fas…